GlycoMimetics与Crescent Bizerma达成收购协议

2024-10-29 19:13

GlycoMimetics (NASDAQ:GLYC) said it has entered into an acquisition agreement with Crescent Biopharma.
After the deal, the firm said it plans to operate under the name Crescent Biopharma.
In support of the deal, a syndicate of investors has agreed to invest $200 million to purchase GlycoMimetics stock and GlycoMimetics pre-funded warrants.
The deal is expected to close in the second quarter of next year.
The firm's cash balance at closing is anticipated to fund operations through 2027.

More on GlycoMimetics